1-12 of 12
Paul Elson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia

Anjali S. Advani, Brenda Cooper, Valeria Visconte, Paul Elson, Ricky Chan, Jennifer Carew, Wei Wei, Sudipto Mukherjee, Aaron Gerds, Hetty Carraway, Aziz Nazha, Betty Hamilton, Ronald Sobecks, Paolo Caimi, Benjamin Tomlinson, Ehsan Malek, Jane Little, Alexander Miron, John Pink, Jaroslaw Maciejewski, Allison Unger, Matt Kalaycio, Marcos de Lima, Mikkael A. Sekeres
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (14): 4231–4237.
https://doi.org/10.1158/1078-0432.CCR-18-3886
Published: 15 July 2019
View article titled, A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia
Open the PDF for A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia in another window
Journal Articles

Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target

Vadim S. Koshkin, Jorge A. Garcia, Jordan Reynolds, Paul Elson, Cristina Magi-Galluzzi, Jesse K. McKenney, Kumiko Isse, Evan Bishop, Laura R. Saunders, Aysegul Balyimez, Summya Rashid, Ming Hu, Andrew J. Stephenson, Amr F. Fergany, Byron H. Lee, Georges-Pascal Haber, Afshin Dowlati, Timothy Gilligan, Moshe C. Ornstein, Brian I. Rini, Mohamed E. Abazeed, Omar Y. Mian, Petros Grivas
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 210–221.
https://doi.org/10.1158/1078-0432.CCR-18-1278
Published: 03 January 2019
View article titled, Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target
Open the PDF for Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target in another window
Includes: Supplementary data
Journal Articles

Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group

Judith Manola, Patrick Royston, Paul Elson, Jennifer Bacik McCormack, Madhu Mazumdar, Sylvie Négrier, Bernard Escudier, Tim Eisen, Janice Dutcher, Michael Atkins, Daniel Y.C. Heng, Toni K. Choueiri, Robert Motzer, Ronald Bukowski
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (16): 5443–5450.
https://doi.org/10.1158/1078-0432.CCR-11-0553
Published: 14 August 2011
View article titled, Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
Open the PDF for Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors

Brian I. Rini, Jorge A. Garcia, Matthew M. Cooney, Paul Elson, Allison Tyler, Kristi Beatty, Joseph Bokar, Tarek Mekhail, R.M. Bukowski, G. Thomas Budd, Pierre Triozzi, Ernest Borden, Percy Ivy, Helen X. Chen, Afshin Dowlati, Robert Dreicer
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6277–6283.
https://doi.org/10.1158/1078-0432.CCR-09-0717
Published: 30 September 2009
View article titled, A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors
Open the PDF for A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors in another window
Journal Articles

Low-Dose Methotrexate Enhances Aminolevulinate-Based Photodynamic Therapy in Skin Carcinoma Cells In vitro and In vivo

Sanjay Anand, Golara Honari, Tayyaba Hasan, Paul Elson, Edward V. Maytin
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (10): 3333–3343.
https://doi.org/10.1158/1078-0432.CCR-08-3054
Published: 18 May 2009
View article titled, Low-Dose Methotrexate Enhances Aminolevulinate-Based Photodynamic Therapy in Skin Carcinoma Cells <em>In vitro</em> and <em>In vivo</em>
Open the PDF for Low-Dose Methotrexate Enhances Aminolevulinate-Based Photodynamic Therapy in Skin Carcinoma Cells <em>In vitro</em> and <em>In vivo</em> in another window
Includes: Supplementary data
Journal Articles

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

Jennifer S. Ko, Arnold H. Zea, Brian I. Rini, Joanna L. Ireland, Paul Elson, Peter Cohen, Ali Golshayan, Patricia A. Rayman, Laura Wood, Jorge Garcia, Robert Dreicer, Ronald Bukowski, James H. Finke
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (6): 2148–2157.
https://doi.org/10.1158/1078-0432.CCR-08-1332
Published: 16 March 2009
View article titled, Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Open the PDF for Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients in another window
Includes: Supplementary data
Journal Articles

Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

James H. Finke, Brian Rini, Joanna Ireland, Patricia Rayman, Amy Richmond, Ali Golshayan, Laura Wood, Paul Elson, Jorge Garcia, Robert Dreicer, Ronald Bukowski
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6674–6682.
https://doi.org/10.1158/1078-0432.CCR-07-5212
Published: 16 October 2008
View article titled, Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
Open the PDF for Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients in another window
Journal Articles

Clinical and Biological Effects of Neoadjuvant Sargramostim and Thalidomide in Patients with Locally Advanced Prostate Carcinoma

Jorge A. Garcia, Eric A. Klein, Cristina Magi-Galluzzi, Paul Elson, Pierre Triozzi, Robert Dreicer
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (10): 3052–3059.
https://doi.org/10.1158/1078-0432.CCR-07-4731
Published: 15 May 2008
View article titled, Clinical and Biological Effects of Neoadjuvant Sargramostim and Thalidomide in Patients with Locally Advanced Prostate Carcinoma
Open the PDF for Clinical and Biological Effects of Neoadjuvant Sargramostim and Thalidomide in Patients with Locally Advanced Prostate Carcinoma in another window
Journal Articles

Prognostic Factors in Patients with Advanced Renal Cell Carcinoma: Development of an International Kidney Cancer Working Group

Ronald M. Bukowski, Sylvie Negrier, Paul Elson
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (18): 6310S–6314S.
https://doi.org/10.1158/1078-0432.CCR-050000
Published: 15 September 2004
View article titled, Prognostic Factors in Patients with Advanced Renal Cell Carcinoma: <subtitle>Development of an International Kidney Cancer Working Group</subtitle>
Open the PDF for Prognostic Factors in Patients with Advanced Renal Cell Carcinoma: <subtitle>Development of an International Kidney Cancer Working Group</subtitle> in another window
Journal Articles

Phase I Trial of Consensus Interferon in Patients with Metastatic Renal Cell Carcinoma: Toxicity and Immunological Effects

Thomas E. Hutson, Luis Molto, Tarek Mekhail, Paul Elson, James Finke, Charles Tannenbaum, Ernest Borden, Robert Dreicer, Thomas Olencki, Ronald M. Bukowski
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (4): 1354–1360.
Published: 01 April 2003
View article titled, Phase I Trial of Consensus Interferon in Patients with Metastatic Renal Cell Carcinoma: <subtitle>Toxicity and Immunological Effects</subtitle>
Open the PDF for Phase I Trial of Consensus Interferon in Patients with Metastatic Renal Cell Carcinoma: <subtitle>Toxicity and Immunological Effects</subtitle> in another window
Journal Articles

Breast Tumor Immunophenotype of BRCA1 -Mutation Carriers Is Influenced by Age at Diagnosis

Susan A. J. Vaziri, Lisa M. Krumroy, Paul Elson, G. Thomas Budd, Gerarda Darlington, Jonathan Myles, Raymond R. Tubbs, Graham Casey
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (7): 1937–1945.
Published: 01 July 2001
View article titled, Breast Tumor Immunophenotype of <em>BRCA1</em> -Mutation Carriers Is Influenced by Age at Diagnosis
Open the PDF for Breast Tumor Immunophenotype of <em>BRCA1</em> -Mutation Carriers Is Influenced by Age at Diagnosis in another window
Journal Articles

Phase I Trial of Exisulind (Sulindac Sulfone, FGN-1) as a Chemopreventive Agent in Patients with Familial Adenomatous Polyposis

Rosalind van Stolk, Gary Stoner, William L. Hayton, Kenneth Chan, Barry DeYoung, Laura Kresty, Brian H. Kemmenoe, Paul Elson, Lisa Rybicki, James Church, Kim Provencher, Denise McLain, Ernest Hawk, Ben Fryer, Gary Kelloff, Ram Ganapathi, G. Thomas Budd
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (1): 78–89.
Published: 01 January 2000
View article titled, Phase I Trial of Exisulind (Sulindac Sulfone, FGN-1) as a Chemopreventive Agent in Patients with Familial Adenomatous Polyposis
Open the PDF for Phase I Trial of Exisulind (Sulindac Sulfone, FGN-1) as a Chemopreventive Agent in Patients with Familial Adenomatous Polyposis in another window